Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: The ELderly and LErcanidipine (ELLE) study

Archives of Gerontology and Geriatrics

Volumn 37, Issue 3, 2003, Pages 203-212

  Cherubini, Antonio ^a   Fabris, Fabrizio ^b   Ferrari, Ettore ^c   Cucinotta, Domenico ^d   Incalzi, Raffaele Antonelli ^e   Senin, Umberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antihypertensive agents; Calcium channel blocker; Hypertension; Lacidipine; Lercanidipine; Nifedipine

Indexed keywords

ANTIHYPERTENSIVE AGENT; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE;

AGED; AGING; ANKLE EDEMA; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FEMALE; FLUSHING; GASTROINTESTINAL TRACT; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; RENOVASCULAR HYPERTENSION; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE;

EID: 0141737128     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(03)00047-5     Document Type: Article

References (22)

1. Treatment of hypertension in adults with diabetes. Diabetes Care. 25:(Suppl. 1):2002;S71-S73.
2. Black H.R., Elliott W.J., Weber M.A., Frishman W.H., Strom J.A., Liebson P.R., Hwang C.T., Ruff D.A., Montoro R., DeQuattro V., Zhang D., Schleman M.M., Klibaner M.I. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension. 38:2001;1118-1123.
3. Blair J., McKlellan K.J. Lercanidipine: a review of its use in hypertension. Drugs. 60:2000;1123-1140.
4. Brown M.J. Matching the right drug to the right patient in essential hypertension. Heart. 86:2001;113-120.
5. Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M., Horan M.J., Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
6. Epstein M. The growing role of calcium antagonists in treating hypertension in the elderly. Am. J. Geriatr. Cardiol. 9:2000;42-48.
7. Franklin S.S., Jacobs M.J., Wong N.D., L'Italien G.J., Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 37:2001;869-874.
8. 1999 World Health Organization: International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens. 17:1999;151-183.
9. Hansson L. Hypertension in the elderly. J. Hypertens. 14:(Suppl. 3):1996;S17-S21.
10. Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press. 7:(Suppl. 2):1998;10-17.
11. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157:1997;2413-2446.
12. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press. 8:1999;92-101.
13. Meredith P.A. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Invest. Drugs. 8:1999;1043-1062.
14. Morgan T.O., Anderson A.I.E., MacInnis R.J. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 14:2001;241-247.
15. Mulrow, C., Lau, J., Cornell, J., Brand, M., 2000. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst. Rev. 2, CD000028.
16. Ostergren J., Isaksson H., Brodin U., Schwan A., Ohman K.P. Effect of amlodipine versus felodipine extended release on 24-h ambulatory blood pressure in hypertension. Am. J. Hypertens. 11:1998;690-696.
17. Psaty B.M., Furberg C.D., Kuller L.H., Cushman M., Savage P.J., Levine D., O'Leary D.H., Bryan R.N., Anderson M., Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. Arch. Intern. Med. 161:2001;1183-1192.
18. Schaefer, R.M., Aldons, P.M., Burgess, E.D., Tilvis, R., Girerd, X., Singh, G.P., Rehn, L., Morgan T.O., For the International Study Group, 1998. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. Int. J. Clin. Pract. 52, 381-386.
19. Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G., Birkenhager W.H., Bulpitt C.J., De Leeuw P.W., Dollery C.T., Fletcher A.E., Forette F., Leonetti G., Nachev C., O'Brien E.T., Rosenfeld J., Rodicio J.L., Tuomilehto J., Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 350:1997;757-764.
20. Staessen J.A., Gasowski J., Wang J.G., Thijs L., Den Hond E., Boissel J.P., Coope J., Ekbom T., Gueyffier F., Liu L., Kerlikowske K., Pocock S., Fagard R.H. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 355:2000;865-872.
21. Wellek S., Michaelis J. Elements of significant testing with equivalence problems. Methods Inform. Med. 30:1991;194-198.
22. Zannad F. The potential advantages of a modern antihypertensive therapy in the elderly. J. Cardiovasc. Pharmacol. 35:(Suppl. 1):2000;S19-S23.